MORF Morphic Holding Inc.

31.07
-0.12  -0%
Previous Close 31.19
Open 31.53
52 Week Low 9.9
52 Week High 34.48
Market Cap $967,057,043
Shares 31,125,106
Float 12,208,533
Enterprise Value $751,732,286
Volume 106,798
Av. Daily Volume 71,321
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
MORF-057
Healthy volunteers
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
MORF-720
Idiopathic pulmonary fibrosis
Phase 1
Phase 1
IND filing due late-2020.

Latest News

  1. WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to participate in the Jefferies Virtual London Healthcare Conference with a Company presentation at 2:55 PM ET on Wednesday, November 18, 2020.

    A live webcast of the company presentation will be available on the Investor section of Morphic's website at www.morphictx.com. An archived replay will be available on the company's website following the conference.

    About Morphic Therapeutic

    Morphic Therapeutic is a biopharmaceutical company developing…

    WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to participate in the Jefferies Virtual London Healthcare Conference with a Company presentation at 2:55 PM ET on Wednesday, November 18, 2020.

    A live webcast of the company presentation will be available on the Investor section of Morphic's website at www.morphictx.com. An archived replay will be available on the company's website following the conference.

    About Morphic Therapeutic

    Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

    Contacts

    Morphic Therapeutic

    Chris Erdman

     

    617.686.1718



    Primary Logo

    View Full Article Hide Full Article
  2. Initiated phase 1 clinical trial for MORF-057 with results expected by mid-2021

    Presented data at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057

    Received $20 million from AbbVie exercising option to αvβ6 integrin inhibitor program

    WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and third quarter 2020 financial results.

    "During the third quarter, Morphic made the most noteworthy progress yet in our mission to deliver the first generation of oral medicines targeting integrin receptors. In September, we announced…

    Initiated phase 1 clinical trial for MORF-057 with results expected by mid-2021

    Presented data at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057

    Received $20 million from AbbVie exercising option to αvβ6 integrin inhibitor program

    WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and third quarter 2020 financial results.

    "During the third quarter, Morphic made the most noteworthy progress yet in our mission to deliver the first generation of oral medicines targeting integrin receptors. In September, we announced that the first healthy volunteers received MORF-057 in a phase 1 clinical trial designed to generate safety and pharmacokinetic data, as well as to measure levels of α4β7 receptor occupancy, a key potential proof-of-concept biomarker in inflammatory bowel disease," said Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic. "MORF-057 is the first in our pipeline of selective integrin inhibitor candidates generated by the MInT Platform to enter clinical trials. Further, AbbVie recently exercised its option to exclusively license our αvβ6 integrin inhibitor program for the treatment of fibrotic diseases. AbbVie's decision further validates the MInT Platform and our team's ability to generate high quality small molecule integrin inhibitors and to design and execute rigorous discovery and development programs."

    Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin, a target for the treatment of inflammatory bowel disease (IBD) with an initial focus on moderate-to-severe ulcerative colitis (UC). The mechanism of α4β7 inhibition to treat IBD has been clinically validated by the approved infused antibody therapy, vedolizumab.

    Third quarter and recent corporate highlights:

    • Initiated a phase 1 clinical trial of MORF-057 in healthy volunteers
      • The randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adults will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of MORF-057; a concurrent food effect study will also be conducted
      • The full data set from the trial is expected to be presented at a major medical conference by mid-2021 with potential release of initial single-ascending dose cohort results in first quarter 2021, including key safety and receptor occupancy data



    • Announced AbbVie exercised its option to exclusively license the αvβ6 integrin inhibitor program for fibrotic diseases



      • AbbVie paid Morphic a license fee of $20.0 million, with future potential regulatory and commercial milestones and royalties from the sales of any commercialized candidates
      • The exclusive license covers Morphic's αvβ6 integrin specific program, including the compounds MORF-720 and MORF-627, discovered from the MInT Platform, Morphic's proprietary platform for the discovery of oral integrin drugs



    • Presented additional preclinical data on the MORF-057 program at United European Gastroenterology (UEG) Week Virtual 2020



      • The UEG data reinforce the high potency and selectivity of MORF-057 for its integrin target, α4β7, through ex vivo human translational biomarkers
      • These data further reinforce the potential for MORF-057 to act through the same clinically validated mechanism as the approved injectable, infused antibody, vedolizumab, but using a potentially more convenient oral small molecule
      • Notably, these data also validated a novel physiologically relevant assay to measure α4β7 receptor occupancy in human whole blood, a key pharmacodynamic marker being studied in the ongoing phase 1 clinical trial of MORF-057

    Financial Results for Third Quarter 2020

    Net income for the quarter ended September 30, 2020 was $5.4 million or $0.17 per share, diluted compared to a net loss of $8.9 million or $0.30 per share, basic and diluted for the same quarter last year.

    • Revenue was $25.8 million for the quarter ended September 30, 2020 compared to $5.7 million for the same quarter last year. The increase was primarily due the receipt of a $20.0 million payment triggered by AbbVie exercising their option to Morphic's αvβ6 program
    • Research and development expenses were $16.0 million for the quarter ended September 30, 2020, compared to $12.6 million in the same quarter last year. The $3.4 million increase year-over-year reflects clinical, development and manufacturing costs associated with our lead wholly owned α4β7 clinical program; and increased personnel-related costs to support continued progress with the company's pipeline
    • General and administrative expenses were $4.8 million for the quarter ended September 30, 2020, compared to $2.9 million in the same quarter last year. The $1.9 million increase year-over-year was primarily attributable to increased headcount and higher professional fees to operate as a public company along with consulting fees associated with ongoing business development activities

    As of September 30, 2020, Morphic had cash, cash equivalents, and marketable securities of $213.1 million, compared to $237.0 million at the end of 2019. Through utilization of at-the-market (ATM) offerings during the third quarter of 2020, Morphic raised net proceeds of $6.3 million. Morphic believes its cash, cash equivalents, and marketable securities balance as of September 30, 2020 will be sufficient to fund operating expenses and capital expenditure requirements into at least the end of 2022.

    About Morphic Therapeutic

    Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT Platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic's or our partners' plans or ability to develop, obtain approval for any indication or disease and/or commercialize any oral small-molecule integrin therapeutics, including MORF-057, MORF-720, MORF-627, and any other candidates in development, the ability of MORF-057 to treat inflammatory bowel disease, the ability of MORF-720 and MORF-627 to treat idiopathic pulmonary fibrosis as well as other fibrotic diseases, the potential impact of the COVID-19 pandemic and the sufficiency of our cash, cash equivalents and investments to fund our operations. Statements including words such as "believe," "plan," "continue," "expect," "will be," "develop," "signal," "potential," "anticipate" or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause Morphic's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Morphic's ability to develop, obtain regulatory approval for and commercialize MORF-057, MORF-720, and other product candidates, the timing and results of preclinical studies and clinical trials, the potential impact of the COVID-19 pandemic, Morphic's ability to protect intellectual property; and other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Morphic specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

    -Financial Tables to Follow-



     
    Morphic Holding Inc.
    Condensed Consolidated Statements of Operations
    (unaudited)
    (in thousands, except share and per share data)
                 
                 
      Three Months Ended Nine Months Ended
    September 30 September 30
       2020   2019   2020   2019 
             
    Collaboration revenue$25,757  $5,675  $39,044  $17,311 
    Operating expenses:       
    Research and development 15,998   12,635   54,877   36,912 
    General and administrative 4,751   2,898   13,368   6,807 
    Total operating expenses 20,749   15,533   68,245   43,719 
    Income (loss) from operations 5,008   (9,858)   (29,201)   (26,408) 
    Interest income, net 231   1,298   1,524   3,480 
    Total other income 231   1,298   1,524   3,480 
    Income (loss) before benefit from

    (provision for) income taxes
     5,239   (8,560)   (27,677)   (22,928) 
    Benefit from (provision for) income taxes 115   (304)   427   (569) 
    Net income (loss)$5,354  $(8,864)  $(27,250)  $(23,497) 
    Net income (loss) per share, basic$0.18  $(0.30)  $(0.90)  $(2.06) 
    Net income (loss) per share, diluted$0.17  $(0.30)  $(0.90)  $(2.06) 
    Weighted-average common shares               
    outstanding - basic 30,533,847   29,999,170   30,368,437   11,393,192 
    Weighted-average common shares               
    outstanding - diluted 32,366,141   29,999,170   30,368,437   11,393,192 



      
    Morphic Holding Inc.
     Condensed Consolidated Balance Sheets 
     (unaudited)
     (in thousands)
         
      September 30, 2020  December 31, 2019 
    Assets   
     Cash, cash equivalents and marketable securities$213,146  $237,016 
     Other current assets 5,255   6,557 
     Total current assets 218,401   243,573 
     Other assets 3,177   3,862 
    Total assets$221,578  $247,435 
         
    Liabilities and Stockholders' Equity   
     Current liabilities$35,578  $35,350 
     Long-term liabilities 55,696   71,167 
     Total liabilities 91,274   106,517 
     Total stockholders' equity 130,304   140,918 
    Total liabilities and stockholders' equity$221,578  $247,435 
            

    Contacts

    Morphic Therapeutic

    Chris Erdman



    617.686.1718

    Media Contact

    Adam Silverstein, Ten Bridge Communications



    917.697.9313

    Primary Logo

    View Full Article Hide Full Article
  3. -Data validate physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α4β7 integrin-
    -MORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel disease-

    WALTHAM, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a poster presentation with new preclinical data on MORF-057 at the UEG Week Virtual 2020 meeting. These new data support the profile of MORF-057 as a potent, selective, and orally available small molecule inhibitor of the integrin α4β7 and establish assays for key clinically relevant biomarkers in the…

    -Data validate physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α4β7 integrin-

    -MORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel disease-

    WALTHAM, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced a poster presentation with new preclinical data on MORF-057 at the UEG Week Virtual 2020 meeting. These new data support the profile of MORF-057 as a potent, selective, and orally available small molecule inhibitor of the integrin α4β7 and establish assays for key clinically relevant biomarkers in the ongoing Phase 1 trial of MORF-057. MORF-057 is in clinical development as an oral small molecule inhibitor of the α4β7 integrin for the treatment of inflammatory bowel disease (IBD) with an initial focus on ulcerative colitis (UC).

    "The data presented at UEG Week 2020 expand on the results from previous studies demonstrating the high selectivity of MORF-057 for its integrin target, α4β7, through ex vivo human translational biomarkers," stated Bruce Rogers, PhD, chief scientific officer of Morphic. "Importantly, with these data, Morphic has validated a physiologically relevant assay to measure α4β7 receptor occupancy in human whole blood, an important pharmacodynamic marker being studied in the ongoing phase 1 trial of MORF-057. We are now focused on the translation of these promising preclinical data into clinical results from the Phase 1 study of MORF-057."

    Details of the Poster Presentation at UEG

    Title: Translational biomarkers for selective, oral, small molecule α4β7 inhibitor MORF-057

    Presenter: Maloy Mangada, PhD, Associate Director Translational Sciences, Morphic Therapeutic Inc.

    Contributors: Maloy Mangada, Naresh S. Redhu, Terence Moy, Ali Hussain, Vinod Yadav, Fu-Yang Lin, Brianna Bannister, Raegan Bonesteel, Sarah St. Gelais, Dan Cui, Andrew Sullivan, Liangsu Wang, Alex Lugovskoy, Kwangsoo Kim, Jessica Pondish, Peter Traber, Peter Linde, Dawn Troast, Cheng Zhong, Kristopher N. Hahn, Matthew G. Bursavich, Jamie Wong, Blaise Lippa, Bruce N. Rogers and Adrian S. Ray

    This UEG poster is available on the Morphic website on the Investor page.

    About MORF-057

    Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease (IBD). α4β7 has been clinically validated as a target for the treatment of IBD by the success of the approved injectable antibody therapeutic vedolizumab. MORF-057 is designed to block the interactions between α4β7 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, substantially reducing lymphocyte migration from the bloodstream into intestinal mucosal tissues and causing inflammation that is associated with IBD.

    About Inflammatory Bowel Disease

    Inflammatory Bowel Disease (IBD) comprises several autoimmune and immune-mediated conditions characterized by chronic inflammation of the gastrointestinal tract. Ulcerative colitis and Crohn's disease are two most common types of IBD. In ulcerative colitis, inflammation is limited to the lining of the colon, whereas in Crohn's disease inflammation can segmentally affect any part of the gastrointestinal tract through the entire thickness of the bowel wall. Symptoms of these conditions include persistent diarrhea, abdominal pain, rectal bleeding, weight loss, and fatigue. Approved medications may not adequately control symptoms for many patients, and some develop complications that require surgical removal of the colon and rectum. According to a report by the Crohn's and Colitis Foundation, as of November 2014, there were approximately 1,687,000 people living with ulcerative colitis and Crohn's disease in the United States, with 71,000 new cases diagnosed per year. Among FDA approved therapies for use in moderate to severe IBD is vedolizumab, an injectable monoclonal antibody inhibitor of the integrin α4β7.

    About Morphic Therapeutic

    Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the MInT Platform's ability to discover drug candidates, Morphic's plans to develop and commercialize oral small-molecule integrin therapeutics, the execution of the phase 1 clinical trial as designed, any expectations about safety, efficacy, timing and ability to commence or complete clinical studies and to obtain regulatory approvals for MORF-057 and other candidates in development, and the ability of MORF-057 to treat inflammatory bowel disease or related indications.

    Statements including words such as "believe," "plan," "continue," "expect," "will," "develop," "signal," "potential," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.

    Forward-looking statements are subject to risks and uncertainties that may cause Morphic's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Morphic's or a partner's ability to develop, obtain regulatory approval for or commercialize any product candidate, Morphic's ability to protect intellectual property, the potential impact of the COVID-19 pandemic and the sufficiency of our cash, cash equivalents and investments to fund our operations. These forward-looking statements speak only as of the date hereof and Morphic specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

    Contacts

    Morphic Therapeutic

    Chris Erdman



    617.686.1718

    Media Contact

    Nichole Sarkis, Ten Bridge Communications



    774.278.8273

    Primary Logo

    View Full Article Hide Full Article
  4. First orally available integrin inhibitor from MInT Platform to enter the clinic
    MORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel disease
    Phase 1 program to assess safety and pharmacokinetics of MORF-057 as well as α4β7 receptor occupancy as a clinically relevant biomarker

    WALTHAM, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the first healthy volunteers have received MORF-057 in a phase 1 clinical trial designed to evaluate MORF-057's safety and pharmacokinetic profile in addition to predictive pharmacodynamic signals. MORF-057…

    First orally available integrin inhibitor from MInT Platform to enter the clinic

    MORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel disease

    Phase 1 program to assess safety and pharmacokinetics of MORF-057 as well as α4β7 receptor occupancy as a clinically relevant biomarker

    WALTHAM, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the first healthy volunteers have received MORF-057 in a phase 1 clinical trial designed to evaluate MORF-057's safety and pharmacokinetic profile in addition to predictive pharmacodynamic signals. MORF-057 is in clinical development as an oral small molecule inhibitor of the α4β7 integrin for the treatment of inflammatory bowel disease (IBD) with an initial focus on ulcerative colitis (UC).

    "Morphic designed MORF-057 with its MInT Platform, a unique platform for the discovery and development of oral integrin drugs, to be a highly selective and potent orally administered inhibitor of the α4β7 integrin, a well-validated target in IBD. The initiation of clinical trials for MORF-057 marks a major step forward in this effort," stated Dr. Peter Linde, MD, chief medical officer of Morphic Therapeutic. "Based on its extensive preclinical data package, we believe that MORF-057 can selectively target the same clinically validated mechanism as the approved injectable antibody, vedolizumab, but utilizing a substantially more convenient oral small molecule. The MORF-057 phase 1 trial is designed to generate safety and pharmacokinetic data, as well as to provide key measures of α4β7 receptor occupancy, at multiple doses being evaluated in this program. These results may provide early clinical proof-of-concept for MORF-057 and we expect to present these data at a major medical conference in the first half of next year."

    About the MORF-057 Phase 1 Clinical Trial

    The phase 1 clinical trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of MORF-057 dosed twice daily across three parts enrolling at least 76 healthy volunteers. The initial part of the phase 1 trial will evaluate single ascending doses in 40 or more volunteers across five or more dose cohorts of MORF-057. The second part of the trial will evaluate multiple ascending doses in 24 or more volunteers across at least three dose cohorts of MORF-057. A third part will evaluate the effect of food on the pharmacokinetic effects of MORF-057 in two cohorts of six subjects, each receiving MORF-057 in fed and fasting states. The phase 1 program is designed to generate important receptor occupancy data in each dose cohort that could potentially provide early clinical proof-of-concept and dose selection guidance for use in future studies of MORF-057.

    About MORF-057

    Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease (IBD). α4β7 has been clinically validated as a target for the treatment of IBD by the success of the approved injectable antibody therapeutic vedolizumab. MORF-057 is designed to block the interactions between α4β7 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, substantially reducing lymphocyte migration from the bloodstream into intestinal mucosal tissues and causing inflammation that is associated with IBD.

    About Inflammatory Bowel Disease

    Inflammatory Bowel Disease (IBD) comprises several autoimmune and immune-mediated conditions characterized by chronic inflammation of the gastrointestinal tract. Ulcerative colitis and Crohn's disease are two most common types of IBD. In ulcerative colitis, inflammation is limited to the lining of the colon, whereas in Crohn's disease inflammation can segmentally affect any part of the gastrointestinal tract through the entire thickness of the bowel wall. Symptoms of these conditions include persistent diarrhea, abdominal pain, rectal bleeding, weight loss, and fatigue. Approved medications may not adequately control symptoms for many patients, and some develop complications that require surgical removal of the colon and rectum. According to a report by the Crohn's and Colitis Foundation, as of November 2014, there were approximately 1,687,000 people living with ulcerative colitis and Crohn's disease in the United States, with 71,000 new cases diagnosed per year. Among FDA approved therapies for use in moderate to severe IBD is vedolizumab, an injectable monoclonal antibody inhibitor of the integrin α4β7.

    About Morphic Therapeutic

    Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the MInT Platform's ability to discover drug candidates, Morphic's plans to develop and commercialize oral small-molecule integrin therapeutics, the execution of the phase 1 clinical trial as designed, any expectations about safety, efficacy, timing and ability to commence or complete clinical studies and to obtain regulatory approvals for MORF-057 and other candidates in development, and the ability of MORF-057 to treat inflammatory bowel disease or related indications.

    Statements including words such as "believe," "plan," "continue," "expect," "will," "develop," "signal," "potential," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.

    Forward-looking statements are subject to risks and uncertainties that may cause Morphic's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Morphic's or a partner's ability to develop, obtain regulatory approval for or commercialize any product candidate, Morphic's ability to protect intellectual property, the potential impact of the COVID-19 pandemic and the sufficiency of our cash, cash equivalents and investments to fund our operations. These forward-looking statements speak only as of the date hereof and Morphic specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

    Contacts

    Morphic Therapeutic

    Chris Erdman



    617.686.1718

    Media Contact

    Tom Donovan, Ten Bridge Communications



    857.559.3397

    Primary Logo

    View Full Article Hide Full Article
  5. WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company overview at 1:00 p.m. ET on the same day.

    A live webcast of the company presentation will be available on the Investor section of Morphic's website at https://www.morphictx.com. An archived replay will be available on the company's website following the…

    WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company overview at 1:00 p.m. ET on the same day.

    A live webcast of the company presentation will be available on the Investor section of Morphic's website at https://www.morphictx.com. An archived replay will be available on the company's website following the conference.

    About Morphic Therapeutic

    Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

    Contacts

    Morphic Therapeutic

    Chris Erdman



    617.686.1718

    Media Contact

    Tom Donovan, Ten Bridge Communications



    857.559.3397

    Primary Logo

    View Full Article Hide Full Article
View All Morphic Holding Inc. News